Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase 1/2 Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; ONO 4578 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 15 Mar 2021 Status changed from recruiting to completed.
    • 31 Jan 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record. (2020-12-29)
    • 14 Nov 2020 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top